Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma

Internal Medicine Journal

Volumn 34, Issue 9-10, 2004, Pages 576-578

  Ross, D M ^a   To, L B ^a   Horvath, Noemi ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Autologous transplantation; Multiple myeloma; Paraprotein; Prognostic factors

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PARAPROTEIN; VINCRISTINE;

ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENCE JONES PROTEIN; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINS; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 8344251663     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00689.x     Document Type: Review

References (4)

1. Hawkins T, Horvath N, Rawling C, Bayly J, Andary C, Dyson P et al. An incremental response to high-dose therapy in multiple myeloma. Bone Marrow Transplant 1996; 17: 929-35.
2. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998; 102: 1115-23.
3. Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97: 153-6.
4. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-43.